1
|
Superparamagnetic maghemite nanoparticles from solid-state synthesis – Their functionalization towards peroral MRI contrast agent and magnetic carrier for trypsin immobilization. Biomaterials 2009; 30:2855-63. [DOI: 10.1016/j.biomaterials.2009.02.023] [Citation(s) in RCA: 130] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2008] [Accepted: 02/12/2009] [Indexed: 11/24/2022]
|
2
|
Small WC, DeSimone-Macchi D, Parker JR, Sukerkar A, Hahn PF, Rubin DL, Zelch JV, Kuhlman JE, Outwater EK, Weinreb JC, Brown JJ, de Lange EE, Woodward PJ, Arildsen R, Foster GS, Runge VM, Aisen AM, Muroff LR, Thoeni RF, Parisky YR, Tanenbaum LN, Totterman S, Herfkens RJ, Knudsen J, Bernardino ME. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis. J Magn Reson Imaging 1999; 10:15-24. [PMID: 10398973 DOI: 10.1002/(sici)1522-2586(199907)10:1<15::aid-jmri3>3.0.co;2-x] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The purpose of this study was to evaluate the safety and efficacy of a manganese chloride-based oral magnetic resonance (MR) contrast agent during a Phase III multisite clinical trial. Two hundred seventeen patients were enrolled who were already scheduled for MRI of the abdomen and/or pelvis. In this group of patients, it was postulated that the use of an oral agent would better allow discrimination of pathology from bowel. Patients with known gastrointestinal pathology including peptic ulcer disease, inflammatory bowel disease, obstruction, or perforation were excluded to minimize confounding variables that could affect the safety assessment. Of these 217 patients, 18 received up to 900 mL of placebo, and 199 patients were given up to 900 mL of a manganese chloride-based oral contrast agent, LumenHance (Bracco Diagnostics, Inc.). Safety was determined by comparing pre- and post-dose physical examinations, vital signs, and laboratory examinations and by documenting adverse events. Efficacy was assessed by unblinded site investigators and two blinded reviewers who compared pre- and post-dose T1- and T2-weighted MRI scans of the abdomen and/or pelvis. In 111 (57%) of the 195 cases evaluated for efficacy by site investigators (unblinded readers), MRI after LumenHance provided additional diagnostic information. Increased information was found by two blinded readers in 52% and 51% of patients, respectively. In 44/195 cases (23%) unblinded readers felt the additional information would have changed patient diagnosis and in 50 patients (26%), it would have changed management and/or therapy. Potential changes in patient diagnosis or management/therapy were seen by the two blinded readers in 8-20% of patients. No clinically significant post-dose laboratory changes were seen. Forty-eight patients (24%) receiving LumenHance and four patients (22%) receiving placebo experienced one or more adverse events. Gastrointestinal tract side effects were most common, seen in 29 (15%) of LumenHance patients and in 3 (17%) of the placebo patients. LumenHance is a safe and efficacious oral gastrointestinal contrast agent for MRI of the abdomen and pelvis.
Collapse
Affiliation(s)
- W C Small
- Department of Radiology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
|
4
|
Bonnemain B. Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A review. J Drug Target 1999; 6:167-74. [PMID: 9888302 DOI: 10.3109/10611869808997890] [Citation(s) in RCA: 295] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Superparamagnetic agents in magnetic resonance imaging: physico-chemical characteristics and clinical applications. Superparamagnetic agents have been the subject of extensive research over the last decade. They consist of iron oxide nanoparticles which are highly effective in Magnetic Resonance Imaging (MRI). The particle size varies widely and influences their physicochemical and pharmacokinetic properties. Their main present and future applications by the parenteral route are: imaging of gastrointestinal tract, liver and spleen, lymph nodes. Ultrasmall superparamagnetic iron oxide particles (USPIO) are also blood pool agents which could be used for perfusion imaging (i.e. brain or myocardial ischemic diseases) as well as for imaging of vessels in Magnetic Resonance Angiography. These agents open up an important field of research into more specific agents adapted to clinicians' needs in diagnostic imaging.
Collapse
Affiliation(s)
- B Bonnemain
- Research and Development, Laboratoire GUERBET, Roissy CDG, France
| |
Collapse
|
5
|
Small WC, Macchi DD, Parker JR, Bernardino ME. Multisite study of the safety and efficacy of LumenHance, a new gastrointestinal contrast agent for MRI of the abdomen and pelvis. Acad Radiol 1998; 5 Suppl 1:S147-50; discussion S156. [PMID: 9561066 DOI: 10.1016/s1076-6332(98)80087-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- W C Small
- Department of Radiology, Emory University School of Medicine, Atlanta, GA 30322, USA
| | | | | | | |
Collapse
|
6
|
Scheidler J, Heuck AF, Meier W, Reiser MF. MRI of pelvic masses: efficacy of the rectal superparamagnetic contrast agent Ferumoxsil. J Magn Reson Imaging 1997; 7:1027-32. [PMID: 9400845 DOI: 10.1002/jmri.1880070614] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The purpose of this study was to determine the potential value of rectally administered Ferumoxsil for pelvic MRI. Twenty patients with suspected rectosigmoid and ovarian tumors were prospectively examined before and after rectal administration of 300 to 600 ml of the superparamagnetic contrast agent Ferumoxsil. Imaging parameters (1.5-T system, phased-array coil, transverse T1-weighted spin echo (SE) and T2-weighted turbo-SE sequences, 6-mm slice thickness, 350-mm field of view [FOV], 512 x 512 matrix) were kept constant. Images were evaluated for tumor presence, lymphadenopathy, bowel involvement, and peritoneal implants. Precontrast and postcontrast studies were rated for bowel delineation, lesion/organ-to-bowel differentiation, presence of artifacts, and confidence of diagnosis. Delineation of rectum and sigmoid colon (P < .001) as well as separation of bowel and vagina, uterus/adnexa, dome of the urinary bladder, lymph nodes, and vessels improved significantly (P < .01) on both T1-weighted and T2-weighted postcontrast sequences. The rectal contrast agent did not increase the level of artifacts. Changes in diagnosis in 7 of 20 patients were mainly due to identification of colorectal tumors or bowel involvement on postcontrast images. The readers' diagnostic confidence was significantly higher on contrast-enhanced than on unenhanced studies (93 +/- 6.4% vs 68 +/- 25.2%). Rectal application of Ferumoxsil improves lesion/organ-to-bowel delineation and overall diagnostic confidence in pelvic MRI.
Collapse
Affiliation(s)
- J Scheidler
- Department of Diagnostic Radiology, Klinikum Grosshadern, Ludwig-Maximilians-University of Munich, Germany.
| | | | | | | |
Collapse
|
7
|
Rubin DL, Falk KL, Sperling MJ, Ross M, Saini S, Rothman B, Shellock F, Zerhouni E, Stark D, Outwater EK, Schmiedl U, Kirby LC, Chezmar J, Coates T, Chang M, Silverman JM, Rofsky N, Burnett K, Engel J, Young SW. A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI. J Magn Reson Imaging 1997; 7:865-72. [PMID: 9307913 DOI: 10.1002/jmri.1880070515] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The purpose of this study was to assess the effectiveness and safety of Gadolite Oral Suspension as a gastrointestinal (GI) contrast agent for MRI in a phase II and two phase III multicenter clinical trials. Gadolite was administered to 306 patients with known or suspected abdominal and/or pelvic disease. MRI with T1- and T2-weighted sequences was performed before and after ingestion. Efficacy was evaluated by having two masked readers rate the certainty of their MR diagnosis (0 = uncertain, 1 = probable, 2 = definite) on randomly presented pre- and post-Gadolite Oral Suspension enhanced images. Principal investigators also evaluated the images and established the final diagnosis. Vital signs, clinical chemistries, and adverse events were documented. Blood and urine samples were analyzed for gadolinium content to determine whether Gadolite Oral Suspension was absorbed systemically. Certainty in MR diagnosis increased significantly (P < .001) for both blinded readers between pre- and post-Gadolite images (.49-1.18 for reader 1: .46-1.53 for reader 2). Sensitivity, specificity, and accuracy also increased for both masked readers. No gadolinium was detected in blood or urine samples. There were no serious adverse events and no apparent drug-related trends in mean vital signs or laboratory values. Gadolite is a highly effective, safe, and well tolerated contrast agent for clinical use with MRI.
Collapse
Affiliation(s)
- D L Rubin
- Good Samaritan Hospital, San Jose, CA, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Ernst O, Sergent G, L'Hermine C. Oral administration of a low-cost negative contrast agent: a three-year experience in routine practice. J Magn Reson Imaging 1997; 7:495-8. [PMID: 9170033 DOI: 10.1002/jmri.1880070308] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
A low cost, well tolerated, and effective gastrointestinal contrast agent is needed for abdominal MRI. The authors tested, in vitro and in routine practice, a mixture of 192 g of barium sulfate (Micropaque HD oral, Guerbet, France) diluted in 500 ml of gastric antacid (Maalox, Rohrer, Fort Washington, PA). Its T1 and T2 relaxation times were 324 and 14 msec, respectively (.2 T). This contrast agent was used in routine practice in 789 patients (.5 T). It had a low signal intensity in 86% and 82% of the cases on T1- and T2-weighted sequences, respectively. No side effect due to magnetic susceptibility was seen, even with gradient-echo sequences. The dilution of barium sulfate in gastric antacid, instead of water, causes a low signal intensity on all sequences for a low barium sulfate concentration (38% w/v). This product is an effective and low cost contrast agent in routine practice.
Collapse
Affiliation(s)
- O Ernst
- Centre Hospitalier Universitaire, Lille, France
| | | | | |
Collapse
|
9
|
Jacobsen TF, Laniado M, Van Beers BE, Dupas B, Boudghène FP, Rummeny E, Falke TH, Rinck PA, MacVicar D, Lundby B. Oral magnetic particles (ferristene) as a contrast medium in abdominal magnetic resonance imaging. Acad Radiol 1996; 3:571-80. [PMID: 8796719 DOI: 10.1016/s1076-6332(96)80222-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
RATIONALE AND OBJECTIVES In this phase III study, we evaluated the efficacy and safety of a negative contrast medium, ferristene (oral magnetic particles), among 277 patients undergoing magnetic resonance (MR) imaging of the abdomen. METHODS Enhanced (800 ml ferristene) MR images were compared with unenhanced MR images in an intraindividual-patient control design. Adverse events were recorded. The examinations were performed on 1.5-T MR systems (T1- and T2-weighted sequences). RESULTS Ferristene increased the diagnostic information in 50.9% of the patients, particularly in those with abdominal masses, lymphoma, or pancreatic disease. Distribution of ferristene in the stomach, duodenum, jejunum, and ileum was complete or sufficient in 70.5-85% of the studies. In 64% of the patients, we were confident in the MR findings after the use of ferristene, and ferristene disclosed additional findings in 22% of the patients. The incidence of adverse events was 9.0%, but only 3.6% of all patients experienced ferristene-related adverse events (e.g., nausea, vomiting). Most events were mild or moderate in intensity. CONCLUSION Ferristene was well tolerated, and for 50% of the patients it added useful diagnostic information.
Collapse
|
10
|
Affiliation(s)
- W Schima
- Department of Radiology, Harvard Medical School, Boston, USA
| | | | | |
Collapse
|
11
|
Young SW, Qing F, Rubin D, Balkus KJ, Engel JS, Lang J, Dow WC, Mutch JD, Miller RA. Gadolinium zeolite as an oral contrast agent for magnetic resonance imaging. J Magn Reson Imaging 1995; 5:499-508. [PMID: 8574032 DOI: 10.1002/jmri.1880050504] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
The purpose of this study was to evaluate efficacy and safety of a gadolinium (Gd) zeolite suspension as an oral MRI contrast agent. Serial dilutions of GADO-LITE Oral Suspension 1,2-300 micrograms of Gd(III)/mL) were prepared. MRI (T1 and T2 weighted) of standards and dogs (precontrast and postcontrast) were performed. Toxicity and Gd absorption were also assessed. Subsequently, 30 normal male adult volunteers were divided into six groups of five subjects each. Gd zeolite po suspension was administered before and after MRI in volumes and concentrations ranging from 250 to 1500 mL; 6 to 60 micrograms of Gd+3/mL. The images were rated (efficacy score) by a blinded reader. Vital signs, blood chemistries and urinalysis were recorded. Gadolite Oral Suspension produced excellent enhancement of the dog gastrointestinal (GI) tract. No toxicity or absorption of Gd was observed in dogs receiving doses up to 4 times the anticipated human dose daily for 14 consecutive days. In clinical trials, Gd zeolite significantly improved the efficacy scores for all groups and all pulsing sequences (all P values < .05). Efficacy scores and signal intensities generally increased with concentration and volume. No Gd was detected in blood or urine specimens. No significant adverse events were reported. Gd zeolite is a promising contrast medium for enhancement of the GI tract in MRI.
Collapse
Affiliation(s)
- S W Young
- Pharmacyclics, Inc., Sunnyvale, CA 94086, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Spencer JA, Golding SJ. Patterns of lymphatic metastases at recurrence of prostate cancer: CT findings. Clin Radiol 1994; 49:404-7. [PMID: 8045065 DOI: 10.1016/s0009-9260(05)81826-4] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
We describe the CT patterns of lymphadenopathy and visceral metastasis in 22 men with clinical features of recurrent prostate cancer. Fifteen of 22 men (68%) had lymphadenopathy with predominant retroperitoneal disease in seven cases, a feature noted particularly in men whose primary treatment had involved radical pelvic radiotherapy. A previously unreported 'pseudolymphoma' pattern of massive retroperitoneal disease with contiguous invasion of the perirenal space and adrenal glands was seen (three cases). Whilst staging examinations with CT (or MRI) at initial diagnosis of prostate cancer may be confined to the pelvis if no pelvic lymphadenopathy is found, evaluation of suspected recurrent disease requires examination of the abdomen and pelvis. CT appearances of advanced prostate cancer may mimic retroperitoneal lymphoma.
Collapse
Affiliation(s)
- J A Spencer
- Regional CT Unit, Churchill Hospital, Oxford
| | | |
Collapse
|